Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
You may also be interested in...
FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says
Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.
FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says
Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.
Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.